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Background and Objectives 
Paediatric blood transfusion for severe anaemia in hospitals in sub-Saharan Africa remains common. 
Yet, reports describing the haematological quality of donor blood or storage duration in routine 
practice are very limited. Both factors are likely to affect transfusion outcomes.  
Materials and Methods  
We undertook 3 audits examining the distribution of pack types, haematological quality and storage 
duration of donor blood used in a paediatric clinical trial of blood at four hospitals in Africa (Uganda 
and Malawi).  
Results 
The overall distribution of whole blood, packed cells (plasma-reduced by centrifugation) and red cell 
concentrates (RCC) (plasma-reduced by gravity-dependent sedimentation) used in a randomised 
trial was 40.7% (N=1215), 22.4% (N=669) and 36.8% (N=1099) respectively. The first audit found 
similar median haematocrits of 57.0% (50.0,74.0), 64.0% (52.0,72.5; p=0.238 vs whole blood) and 
56.0% (48.0,67.0; p=0.462) in whole blood, RCC and packed cells respectively, which resulted from 
unclear pack labelling by blood transfusion services (BTS). Retraining of the BTS, hospital blood 
banks and clinical teams led to, in subsequent audits, significant differences in median haematocrit 
and haemoglobins across the 3 pack types and values within expected ranges. Median storage 
duration time was 12 days (IQR 6,19) with 18.2% (537/2964) over 21 days in storage. Initially, 9 
(2.8%) packs were issued past the recommended duration of storage, dropping to 0.3% (N=7) in the 
third audit post training.    
Conclusion 
The study highlights the importance of close interactions and education between BTS and clinical 
services and the importance of haemovigilence to ensure safe transfusion practice.   
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INTRODUCTON 
The availability of safe blood for transfusion is fundamental for every health care system. Quality-
assurance practices are a legal requirement for blood transfusion services (BTS) in high-income 
countries to minimise patient risk. Yet, even within this context the prolonged storage of donor blood 
remains controversial [1-3], since transfusions given to critically ill patients with longer storage age 
have resulted in unintended, adverse consequences [1, 4, 5]. In sub-Saharan Africa (sSA), where 
the demand for transfusion is high, little research has been conducted on the quality and safety of 
donor blood or how these effect post-transfusion outcomes. With regard to the safety of blood most 
studies or reviews have focused on the risks of transfusion-transmitted infections (TTIs) [6], with a 
smaller number investigating the microbiological hazards [7]. To our knowledge no previous studies 
have been conducted within sSA that have investigated the haematological quality or storage age 
of donor blood under routine operational conditions. 
 
Children are the main recipients of blood transfusions in sSA, where severe anaemia remains a 
leading cause of both admission to hospital and of direct mortality [8], and is a major factor in the 
estimated 600,000 malaria deaths each year [9]. We are currently investigating the impact of the 
World Health Organization (WHO) transfusion guidelines on within-hospital and post-discharge 
paediatric survival in a multicentre phase III clinical trial entitled Transfusion and Treatment of Severe 
Anaemia in African Children: a randomised controlled Trial (TRACT; ISRCTN 84086586) [10]. 
TRACT is being conducted at four hospitals in sSA: three in Uganda (Mulago National Referral 
Hospital (NRH) and the Mbale and Soroti Regional Referral Hospitals (RRH)) and at one hospital in 
Malawi (Queen Elizabeth Central Hospital in Blantyre). One interventions that TRACT is 
investigating is a higher versus a standard volume of transfused blood (calculated in millilitres per 
kilogram of the child’s bodyweight).  In theory, the volume of blood given should translate to a 
predictable red cell mass being transfused. However, we were unable to find any data on 
haematological quality control to support this assumption in the settings where the trial was being 
conducted. Moreover, a further challenge to implementing a protocol to ensure clear separation 
between the two transfusion volume strategies was that BTS supplied three different pack-types: 
whole blood, red cell concentrates (RCC) and packed cells (Figure 1). We also investigated the 
storage age of the blood, that is the time from donation to blood transfusion, as concerns have been 
raised about the quality of blood stored beyond 23 days (‘old blood') [11, 12] even when blood is 
leucocyte-reduced and storage is quality-assured. In most countries in sSA donated blood is not 
leucocyte-reduced during its processing and maintaining a cold-chain is often a challenge [13].  
 
Here, we report the results of audits conducted at different time points during the TRACT trial to 
investigate the haematological quality and storage duration of donor blood packs provided by BTS 
at the four trial centres at three time points during the course of the TRACT trial. In addition, in order 
for practising clinicians to be better informed about the transfusions they regularly prescribe we also 
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include a description of processes of preparation of the different pack-types available for transfusion, 
which were integral to the interpretation of the findings of our audits.  
  
MATERIALS AND METHODS  
In Uganda, the processing and supply of donor packs to Mulago NRH was done by Nakasero 
National BTS while Mbale and Soroti RRHs received supplies from Mbale Regional BTS. In Malawi, 
Blantyre Regional BTS processed and supplied blood to Queen Elizabeth Central Hospital.   
 
Quality Assurance 
The haemoglobin and haematocrit values of all donor blood packs were verified within the trial using 
an aliquot, collected from the blood line prior to the start of each transfusion. In order to accurately 
calculate volumes of blood received by children in the trial, all donor packs were weighed before 
transfusion.  The packs were then gently agitated until well-mixed before being run into a gauged 
(and filtered) ‘burette giving-set’ and then through the infusion line to the intravenous infusion or 
giving-set. The first few drops of blood released from the giving-set were collected under sterile 
conditions into a 2ml apex tubes before infusion lines were connected to patients’ cannulae. 
Haemoglobin values were measured at the bedside using the HemoCue Hb301 system (HemoCue 
AB, Angelholm, Sweden), quality-controlled with Eurotrol Hb301 Control reagents (Eurotrol, USA) to 
ensure accuracy. Haematocrits were determined by centrifugation in capillary tubes (Hematospin 
1300, Hawksley and Sons Ltd). In addition, the clinical team recorded the pack identifier numbers, 
the pack type as issued by the transfusion laboratories (whole blood, packed cells or RCC), the 
blood volume, calculated as the weight of the pack minus the weight of the pack type containing no 
donor blood, and the date of collection from the donor (in order to calculate storage age). Prior to 
the start of the trial we conducted training sessions on procedures for collecting this information. We 
conducted three audits examining donor blood data during the trial: (1) at the beginning of the trial 
during September 2014–January 2015 (Audit 1); (2) following a period of consultation with the BTS 
(February–May 2015; Audit 2); and (3) following a period of re-training during June 2015–January 
2016 (Audit 3). The duration of storage of donor blood before transfusion was categorised as short 
(£14 days), long (15-42 days) or expired (>35 days for whole blood and >42 days for RCC and 
packed cells) [12].  
 
Statistical analysis 
Primary comparison was across pack types within a single audit because of expected differences, 
and secondary comparisons were across audits within a specific pack type to look for 
changes. Comparison was done using Kruskal-Wallis equality-of-populations rank test and Wilcoxon 






A total of 2983 transfusion blood packs were utilised in the trial between September 2014 and 
January 2016. Through our audits, we found that three pack types produced by local BTS were 
supplied for use in the trial: (1) whole blood, collected from donors and stored without any 
preparation; (2) packed cells, produced by centrifugation, to removal platelets and plasma, followed 
by the addition of sodium, adenine, glucose and mannitol (SAGM) solution; and (3) "red cell 
concentrates" (RCCs), which were supplied in Uganda only. RCCs were produced by gravity-
dependent sedimentation as an alternative to centrifugation because of limited capacity for 
mechanical separation. The process of gravity-dependent sedimentation involved packs being hung 
at room temperature overnight before plasma was decanted off and SAGM added in a closed system 
of bags. On the basis of the preparation methods used, packed cells should evidently be the most 
concentrated followed by RCCs and then whole blood (Figure 1). The overall distribution of whole 
blood, packed cells and RCCs included in our three audits was 40.7% (N=1215), 22.4% (N=669) 
and 36.8% (N=1099) respectively. The first, second and third audit included 330, 606 and 2047 
packs respectively. Haemoglobin and haematocrit values were available for 2970 and 2737 donor 
packs respectively. 
 
Haematogical quality of donor blood 
First audit 
In the first audit which was undertaken in Uganda only, we found statistically significant (not 
explained by chance alone) but only moderate differences of haematological values between the 
pack types. The median haemoglobin level was 16.4g/dl (IQR 14.0, 18.8; N=130) in whole blood 
packs, 17.3g/dL (15.4, 19.4; N=136 p<0.001 versus whole blood) in RCC and 18.9 g/dL (17.3, 20.6; 
N=62; p=0.025) in packed-cell packs. Moreover, we found no significant differences between pack 
types in terms of haematocrit values, the medians being 57.0% (50.0, 74.0), 64.0% (52.0, 72.5; 
p=0.238) and 56.0% (48.0, 67.0; p=0.462) in whole blood, RCC and packed cells respectively (Table 
1 and Figure 2A). Median haemoglobin and haematocrits values for the whole blood packs were 
also substantially higher than the expected values of 12g/dl and 35-45% respectively. Conversely, 
the medians were lower than those expected (20g/dl and 55-57% respectively) among packed cell 
donations (Figure 1)[14]. 
 
Quality assurance of research methods 
Because these results were unexpected, we were concerned that there may have been a 
methodological flaw in our sampling technique. To better understand the lack the expected 
differences between the three pack types in terms of their haematological indices, we re-checked 
the methods of sample collection, the reliability of our haemoglobin and haematocrit readings and 
the way in which the pack types were labelled by the BTS. In a sample of ten donor packs from each 
of the 3 Ugandan study centres, we audited the measurement of haemoglobin and haematocrit 
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values against values from automated blood analysers. For sample collection, we compared these 
measurements in samples of donor blood collected in the prescribed manner (at the point of exit 
from the giving set) to samples collected from the top of the burette. Neither assay method nor 
sampling point suggested any methodological explanations for the observed lack of clear 
haematological differences between donor pack types (Supplementary Table 1). Consultation with 
the BTS centres suggested a low emphasis on providing clear labelling instructions for clinicians 
regarding the pack types. This lead to a subsequent change in pack labelling and our realization of 
the need for a series of training sessions for BTS and blood bank staff and clinicians (including trial 
staff) on the importance of pack type identification and labelling.  
 
Second and third audits 
Audit 2, conducted after a period of intense training, included 606 donor packs while Audit 3 involved 
2047 donor packs. In both these subsequent audits we found clear and significant differences 
between the three pack types in terms of haemoglobin and haematocrit (Table 1 and Figures 3 A 
and B) and between countries (Table 2). Linear regression analysis showed a clear relationship 
between pack-type and both haemoglobin and haematocrit values in which, as originally expected, 
the lowest values were seen in whole blood and the highest in packed cells (Figure 2B and 2C). Only 
5.5% (N=164) of the packs had haemoglobin concentrations that were out of range (2 standard 
deviations above or below the mean for each of the pack types).  
 
Storage time 
Data on the age (or storage time) for 2964 donor packs was collected prospectively throughout the 
TRACT trial.  Storage time was highly heterogeneous, with the median age of transfused blood being 
12 days (IQR 6,19) and a range of 0–77 days. Overall, 18.2% (N=537) of the blood used in the trial 
was classified as old (above 21 days of age, Table 3).   The median age of blood before training 
(Audit 1) was 15 (IQR 10-21) days and after training (Audits 2 & 3) was 11 (IQR 6-18) days (p<0.001). 
Through our audits we demonstrated that 9 (2.8%) blood packs used earlier in the trial (Audit 1) were 
issued past the recommended duration of storage. This proportion reduced to 1.0% (N=6) and 0.3% 
(N=7) in the Audits 2 and 3 respectively.  
 
DISCUSSION 
One of the key findings of this study was that, unexpectedly, despite US President's Emergency Plan 
for AIDS Relief (PEPFAR) strengthening of the Ugandan BTS which included the introduction of 
prepared RCC, Audit 1 demonstrated negligible differences in haematological indices between the 
three pack types.  Suboptimal pack labelling in Uganda resulted in the early part of the trial having 
some inadvertent non-adherence to ‘blood volume’ (a proxy for red call mass) randomisation 
strategies. Reviewing all prescribed packs, and identifying the correct pack type as opposed to what 
the clinician had inadvertently believed had been provided, during the first 4 months of the trial, non-
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adherence to randomised transfusion volume was approximately 77% following the protocol, 
although at the time of the transfusion clinicians’ prescriptions were correct for the blood volume 
based on what they understood had been provided. Since, then we observed improvement in 
protocol adherence following training with non-adherence to randomised blood volumes between 
February and May 2015 reduced to 7%.   
 
 
A second finding during the initial audit period was that 2.8% of blood prescribed had exceeded its 
recommended storage period. Consultation between the BTS and clinical teams lead to changes to 
standard operating procedures used by the BTSs and hospital transfusion laboratories was 
subsequently implemented. This resulted in improved quality of blood. As evidenced by subsequent 
audits we were able to demonstrate significant difference in haemoglobin and haematocrit of the 
three pack types after the consultation and training and the proportion of “expired blood” used by the 
clinical teams was also significantly reduced. 
 
For more than a decade, driven by safety concerns that blood transfusions may have been a factor 
in HIV transmission, multilateral donors including PEPFAR, have provided technical and financial 
support to national BTS in low-income countries in sSA, with a view to improving the quality-assured 
screening of all donated blood for transfusion transmissible infections. This has greatly increased 
blood supply and reduced transfusion transmissible infections, as previously reported [15, 16]. 
However, the implementation of such recommendations has also resulted in the adoption in these 
countries of BTS practices and policies from high-income countries, including the centralization of 
BTSs and the preparation of components in place of the use of whole blood. Concerns have been 
raised that centralisation may adversely impact on the equitable and timely access to blood 
transfusion [17]. Moreover, component preparation policies are costly and time-consuming and 
result in delays between collection from donors and supply to local blood banks, thus increasing the 
storage times of blood. Finally, although there appears to be a mismatch between transfusion 
guidelines incorporating recommendations for standard volumes of whole blood and packed cells 
(median donor haemoglobin~20g/dl), the same does not seem to be true but for RCCs (median 
donor haemoglobin~15g/dl) which in some countries are the largest proportion of donor blood pack 
now being issued from PEPFAR-compliant BTSs. This inconsistency between guidelines and donor 
packs in use has implications for the volume and number of packs of blood required to achieve a 
similar degree of haemoglobin correction in a recipient and might therefore impact on clinical 
outcomes, including survival.  In the case of paediatric transfusion, WHO recommends a standard 
volume for transfusion (20mls/kg of whole blood or 10 mls/kg of packed cells) for all children with 
profound (Hb <4/g/dl) or severe and complicated (Hb <6/g/dl plus one or more severity features) 
anaemia, but gives no guidelines for RCCs. Thus, the increasing production of RCCs by BTSs may 
result in many children being initially under-transfused, increasing the need for re-transfusion, an 
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issue observed in a previous study [18].  Worldwide there is little evidence to support the exclusive 
use of red cell concentrates, which in our experience were a third of blood packs issued by BTS. 
Most blood products used in hospitals in Africa are generally for emergency transfusion [19], to 
replacing lost volume (pregnancy related emergencies) and trauma or paediatric transfusion for life 
threatening anaemia, for which paediatric guidelines suggest are better treated with whole blood 
than blood components [17, 20].  
 
Numerous challenges face BTS in sSA, including lack of adequate finance; adequate infrastructure; 
safe blood donors; unbroken supply of consumables and reagents, limited man-power to process 
collected blood, stock outs of screening reagents, lack of transport for transportation of packs to 
regional blood banks and regular power-outages. Such challenges threaten the safe preparation of 
RCCs by gravity-dependent sedimentation, and also result in sub-optimal storage conditions. 
Moreover, processing at regional BTS leads to delays between donation, processing and distribution 
across the regional hospital services which can contribute to prolonged storage times. Prior to the 
trial beginning, we believed that pressure from demand would mean that ‘old blood’ would be rare.  
Instead, we found that the age of blood supplied during TRACT was quite diverse, and included 
some packs that should have been discarded as they were “expired”. Prolonged storage may result 
in adverse consequences owing to red cell changes (the storage lesion) that may render them less 
effective as oxygen carriers and lead to an accumulation of metabolites and cytokines that may lead 
to untoward side effects [21, 22]. The TOTAL trial, conducted in 270 Uganda children investigated 
whether leucocyte-reduced RCCs stored for 25-35 days lead to worse outcomes than packs stored 
for 10 or less days. Lactate clearance, the primary endpoint, was not inferior in those receiving 
prolonged compare to short storage donor blood, as were all other secondary endpoints including 
mortality [23]. Educating both BTS staff and clinicians to not issue or use blood transfusions that 
have gone beyond their expiry date is clearly important. In this respect, it is also worth noting that in 
the African health system, there is little formal training of clinicians in haemovigilence and there are 
no reporting systems similar to the SHOT (serious hazards of transfusion) scheme in the UK [24]. 
Thus, despite being a major issue for research in other parts of the world, there remains uncertainty 
over whether prolonged storage of non-leucocyte reduced blood under standard storage conditions 
impacts on patient outcome in SSA.  
 
Finally, it is important to point out that donated blood issued for  transfusion by BTSs or hospitals 
blood banks in sSA is likely to have several differences compared with high-income countries. 
Beyond the issues of quality assurance and lack of leucocyte depletion are the genetic diversity of 
donors, as many have inherited red cell disorders (including a-thalassaemia, sickle cell trait and 
glucose-6-phosphate dehydrogenase deficiency) [25, 26], all of which are associated with shorter 
red cell half-lives. As a result, this requires locally generated research studies to help African health 
services refine their blood donation practices and policies. We suggest that the findings of our first 
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audit reflect the reality of paediatric transfusion across similar settings that have transitioned from 
the exclusive use of whole blood to include a majority of packs prepared as RCCs, which are not 
currently recognised in treatment guidelines, nor has there been a concerted effort to inform 
clinicians about how this may affect transfusion practice.   
 
ACKNOWLEDGEMENTS 
We would like to thank the children and families who participated in the trial and the trial staff 
members who managed the patients.  
 
AUTHOR CONTRIBUTIONS 
POO, SK, ROO, MM, NK were responsible for acquisition of the data. BM, DK and BW were 
responsible for coordination of blood transfusion service, training and review and interpretation of 
the donor pack data.  S.U., E.C.G., A.M., S.W., T.N.W. IB and K.M. reviewed and managed the 
project and analysed the data provided. All authors contributed to the design of the study and review 







1. Holst LB, Petersen MW, Haase N, Perner A, Wetterslev J: Restrictive versus 
liberal transfusion strategy for red blood cell transfusion: systematic review 
of randomised trials with meta-analysis and trial sequential analysis. Bmj 
2015, 350:h1354. 
2. Lacroix J, Hebert PC, Fergusson DA, Tinmouth A, Cook DJ, Marshall JC, Clayton L, 
McIntyre L, Callum J, Turgeon AF et al: Age of Transfused Blood in Critically Ill 
Adults. The New England journal of medicine 2015. 
3. McQuilten ZK, French CJ, Nichol A, Higgins A, Cooper DJ: Effect of age of red 
cells for transfusion on patient outcomes: a systematic review and meta-
analysis. Transfus Med Rev 2018, 32(2):77-88. 
4. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale 
M, Schweitzer I, Yetisir E: A multicenter, randomized, controlled clinical trial of 
transfusion requirements in critical care. Transfusion Requirements in Critical 
Care Investigators, Canadian Critical Care Trials Group. The New England 
journal of medicine 1999, 340(6):409-417. 
5. Lacroix J, Hebert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, Gauvin F, 
Collet JP, Toledano BJ, Robillard P et al: Transfusion strategies for patients in 
pediatric intensive care units. The New England journal of medicine 2007, 
356(16):1609-1619. 
6. Bloch EM, Vermeulen M, Murphy E: Blood transfusion safety in Africa: a 
literature review of infectious disease and organizational challenges. Transfus 
Med Rev 2012, 26(2):164-180. 
7. Hassall O, Maitland K, Pole L, Mwarumba S, Denje D, Wambua K, Lowe B, Parry 
C, Mandaliya K, Bates I: Bacterial contamination of pediatric whole blood 
transfusions in a Kenyan hospital. Transfusion 2009, 49(12):2594-2598. 
8. de Benoist B ME, Egli I, Cogswell M: : Worldwide prevalence of anaemia 1993–
2005 : WHO global database on anaemia. WHO report 2008 2008. 
9. Organization WH: World Malaria Report. In. Geneva; 2017. 
10. Mpoya A, Kiguli S, Olupot-Olupot P, Opoka RO, Engoru C, Mallewa M, Chimalizeni 
Y, Kennedy N, Kyeyune D, Wabwire B et al: Transfusion and Treatment of 
severe anaemia in African children (TRACT): a study protocol for a 
randomised controlled trial. Trials 2015, 16:593. 
11. Steiner ME, Ness PM, Assmann SF, Triulzi DJ, Sloan SR, Delaney M, Granger S, 
Bennett-Guerrero E, Blajchman MA, Scavo V et al: Effects of red-cell storage 
duration on patients undergoing cardiac surgery. The New England journal of 
medicine 2015, 372(15):1419-1429. 
12. Cooper DJ, McQuilten ZK, Nichol A, Ady B, Aubron C, Bailey M, Bellomo R, 
Gantner D, Irving DO, Kaukonen KM et al: Age of Red Cells for Transfusion and 
Outcomes in Critically Ill Adults. The New England journal of medicine 2017, 
377(19):1858-1867. 
13. Global status report on blood safety and availability 2016. Geneva: World 
Health Organization;: World Health Organization; 2017. 
14. WHO: The Clinical use of Blood Handbook. 2002. 
15. CDC: Progress toward strengthening blood transfusion services---14 
countries, 2008--2010. MMWR 2011, 60:1578--1582. 
16. CDC: Progress toward strengthening blood transfusion services---14 
countries, 2003--2007. MMWR 2008, 57:1273-1277. 
17. Ala F, Allain JP, Bates I, Boukef K, Boulton F, Brandful J, Dax EM, El Ekiaby M, 
Farrugia A, Gorlin J et al: External financial aid to blood transfusion services in 
sub-Saharan Africa: a need for reflection. PLoS medicine 2012, 9(9):e1001309. 
	 11	
18. Kiguli S, Maitland K, George EC, Olupot-Olupot P, Opoka RO, Engoru C, Akech 
SO, Nyeko R, Mtove G, Reyburn H et al: Anaemia and blood transfusion in 
African children presenting to hospital with severe febrile illness. BMC Med 
2015, 13:21. 
19. Global status report on blood safety and availability 2016. In. Geneva: World 
Health Organization; 2017. 
20. Pocket book of hospital care for children: Second edition Guidelines for the 
management of common childhood illnesses. Geneva: World Health 
Organization; 2013. 
21. Bennett-Guerrero E, Veldman TH, Doctor A, Telen MJ, Ortel TL, Reid TS, Mulherin 
MA, Zhu H, Buck RD, Califf RM et al: Evolution of adverse changes in stored 
RBCs. Proc Natl Acad Sci U S A 2007, 104(43):17063-17068. 
22. Spinella PC, Sparrow RL, Hess JR, Norris PJ: Properties of stored red blood 
cells: understanding immune and vascular reactivity. Transfusion 2011, 
51(4):894-900. 
23. Dhabangi A, Ainomugisha B, Cserti-Gazdewich C, Ddungu H, Kyeyune D, Musisi E, 
Opoka R, Stowell CP, Dzik WH: Effect of Transfusion of Red Blood Cells With 
Longer vs Shorter Storage Duration on Elevated Blood Lactate Levels in 
Children With Severe Anemia: The TOTAL Randomized Clinical Trial. JAMA 
2015, 314(23):2514-2523. 
24. Bolton-Maggs PH, Cohen H: Serious Hazards of Transfusion (SHOT) 
haemovigilance and progress is improving transfusion safety. Br J Haematol 
2013, 163(3):303-314. 
25. Aneke JC, Ibeh NC, Okocha CE, Orakpor E: Evaluation of glucose-6-phosphate 
dehydrogenase enzyme deficiency and methemoglobin concentration in 
blood donors in a Nigerian Tertiary hospital-based blood bank. Global Journal 
of Transfusion medicine 2017, 2(2):137-142. 
26. Antwi-Baffour S, Asare RO, Adjei JK, Kyeremeh R, Adjei DN: Prevalence of 
hemoglobin S trait among blood donors: a cross-sectional study. BMC 
Research Notes 2015, 8:583-588. 
 
	 12	
Figure and legends 
 
Figure 1 Summary of the blood preparation process and expected haemoglobin and 
haematocrit values 
Figure 2 Scatter plots of haemoglobin and haematocrit values for the blood packs used at 
start of the trial (A), during the training period (B) and post-training (C). 
 
Figure 3 Box plots of haematocrit (A) and haemoglobin (B) before (Sep2014-Jan2015) and 
after training (Feb2015-Jul2016) by pack type  
 
Legend  
WB: whole blood, RCC: red cell concentrates and PC: packed cells)  
 * p<0.05, ** p<0.001 
 
Appendices:  
Supplementary Table Table S1. Comparison of sample collection and analysis methods at 
three TRACT trial sites in Uganda.  
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N Audit 1 N Audit 2 N Audit 3 P* 
Hb WB 12 130 16.4  
(14.0, 18.8) 





(g/dL) RCC 15 136 17.3  
(15.4, 19.4) 





 PC 20  62 18.9 
(17.3, 20.6) 





          
HCT WB 35-45 111 57.0 
(50.0, 74.0) 





(%) RCC 50-70 124 64.0  
(53.0, 72.5) 





 PC 55-75 19 56.0  
(48.0, 67.0) 





          
Note: significant p<0.001 differences between pack types within audit 2 and audit 3 were found for 
both haemoglobin and haematocrit 
 
WB Whole blood; RCC Red Cell Concentrates; PC Packed Cell 
*P - Kruskal-Wallis equality-of-populations rank test   
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Table 2. Summary of median (IQR) haemoglobin (g/dL) and haematocrit (%) in audits 2 and 6 
stratified by country  
 
 
Pack type  N Audit 2 
Haemoglobin 
P* N Audit 3 
Haemoglobin 
P* 
Whole blood Malawi 71 13.7 (12.8, 14.5)  395 13.5 (12.6, 14.3)  
 Uganda 62 15.2 (13.6, 17.4) <0.001 553 14.1 (12.4, 16.5) <0.001 
Packed cells Malawi 10 19.2 (17.2, 19.9)  83 20.6 (18.9, 21.5)  
 Uganda 100 19.5 (18.0, 21.2) 0.333 408 19.4 (17.7, 21.1) 0.003 
 
 
Pack type  N Audit 2 
Haematocrit 
P* N Audit 3 
Haematocrit 
P* 
Whole blood Malawi 73 41.0 (38.0, 47.0)  386 39.0 (36.0, 41.0)  
 Uganda 54 47.1 (42.0, 55.0) <0.001 526 46.0 (40.0, 57.0) <0.001 
Packed cells Malawi 9 55.0 (49.0, 57.0)  79 56.0 (53.0, 59.0)  
 Uganda 82 59.0 (54.1, 62.0) 0.101 402 62.0 (57.5, 68.0) <0.001 
 






Table 3. Storage duration profiles of blood packs used in the trial. 
 
Duration of storage Audit 1 Audit 2 Audit 3 Total 
Short (0-14 days) 99 (30.5) 162 (26.9) 940 (46.1) 960 (40.5) 
Long (15-42 days) 216 (66.7) 435 (72.1) 1092 (53.6) 1733 (58.8) 
Expired*  9 (2.8) 6 (1.0) 7 (0.3) 22 (0.7) 
Total 324 603 2039 2,956 
 
N (%) *Expired (>35 days for whole blood and >42 days for red cell concentrates and packed 
cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
